Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis?

Joint Bone Spine. 2024 May;91(3):105662. doi: 10.1016/j.jbspin.2023.105662. Epub 2023 Nov 15.

Authors

Philippe Goupille¹, Daniel Wendling²

Affiliations

¹ Rheumatology Department, Trousseau Hospital, CHU de Tours, EA 6295, University of Tours, avenue du la République, 37044 Tours cedex 9, France. Electronic address: goupille@med.univ-tours.fr.
² Rheumatology Department, CHU de Besançon, EA 4266, University of Franche-Comté, Besançon, France.

PMID: 37977524
DOI: 10.1016/j.jbspin.2023.105662

No abstract available

Keywords: Axial spondyloarthritis; C-reactive protein; Treatment.

Publication types

Editorial
Letter

MeSH terms

Adult
Antirheumatic Agents / therapeutic use
Axial Spondyloarthritis* / blood
Axial Spondyloarthritis* / diagnosis
Axial Spondyloarthritis* / drug therapy
Biological Products / therapeutic use
Biomarkers / blood
C-Reactive Protein* / analysis
Female
Humans
Interleukin-17* / antagonists & inhibitors
Male
Spondylarthritis / blood
Spondylarthritis / diagnosis
Spondylarthritis / drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha* / antagonists & inhibitors

Substances

Interleukin-17
C-Reactive Protein
Tumor Necrosis Factor-alpha
Biological Products
Biomarkers
Antirheumatic Agents